Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.89 |
| ▸ | NPC1 | O15118 | 2/20 | 0.89 |
| ▸ | RAB9A | P51151 | 2/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31170269 | 1.00 | SMN1; SMN2 (0.89) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL31449815 | 0.96 | SMN1; SMN2 (0.87) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL205216 | 0.94 | SMN1; SMN2 (1.00) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Hydrochloric Acid SCHEMBL3097843 | 0.93 | SMN1; SMN2 (0.97) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Bicarbonate SCHEMBL3906615 | 0.89 | SMN1; SMN2 (0.89) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| Bicarbonate SCHEMBL3906619 | 0.89 | SMN1; SMN2 (0.89) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL3277860 | 0.89 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL1933206 | 0.89 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL204145 | 0.89 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL9571856 | 0.88 | SMN1; SMN2 (0.87) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2018-09-06 | — | — | US | disclosed |
| US-9994594-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2017-06-29 | — | — | US | disclosed |
| CN-103068830-B | Arginase inhibitors and therapeutic uses thereof | 马尔斯公司 | 2016-06-29 | — | — | CN | disclosed |
| CN-104876955-A | Inhibitors Of Arginase And Their Therapeutic Applications | MARS INC | 2015-09-02 | — | — | CN | disclosed |
| US-9040703-B2 | Inhibitors of arginase and their therapeutic applications | MARS, INCORPORATED (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2014-12-18 | — | — | US | disclosed |
| CN-103068830-A | Arginase inhibitors and therapeutic uses thereof | MARS INC | 2013-04-24 | — | — | CN | disclosed |
| EP-2560978-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | Mars, Incorporated (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED | 2012-04-05 | — | — | US | disclosed |
| WO-2011133653-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS, INCORPORATED (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-05-05 | — | — | US | disclosed |
| CN-102015636-A | Azetidines and cyclobutanes as histamine H3 receptor antagonists | EVOTEC NEUROSCIENCES GMBH | 2011-04-13 | — | — | CN | disclosed |
| EP-2300422-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180251479-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
| US-20110105459-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | SMN1; SMN2 4264/4885NPC1 2956/4885RAB9A 1843/4885 |
| US-20170183362-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
| US-20120083469-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
| US-20140371175-A1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | ARG1, ARG2, PRMT9 | SMN1; SMN2 3556/4885NPC1 2297/4885RAB9A 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.